Literature DB >> 28718983

Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia.

Sri Harsha Tella1,2, Hayet Amalou3, Bradford J Wood3, Richard Chang4, Clara C Chen5, Cemre Robinson2, Michelle Millwood2, Lori C Guthrie2, Sheng Xu3, Elliot Levy3, Venkatesh Krishnasamy3, Rachel I Gafni2, Michael T Collins2.   

Abstract

Tumor-induced osteomalacia (TIO) is a debilitating paraneoplastic condition caused by small phosphaturic mesenchymal tumors (PMTs) that secrete large amounts of the phosphate-regulating and vitamin D-regulating hormone, FGF23. Tumor removal results in cure. However, because of high perioperative comorbidity, either from tumor location or host factors, surgery is sometimes not an option. Tumor destruction via cryoablation may be an effective option for inoperable PMTs. Three subjects with a confirmed diagnosis of TIO were studied. All three underwent cryoablation of suspected PMTs rather than surgery due to significant medical comorbidities or challenging anatomical location. Subject 3 had tumor embolization 24 hours prior to cryoablation because of the size and hypervascularity of the tumor. The success of the tumor cryoablation was defined by normalization of serum phosphate and FGF23. Cryoablation resulted in a rapid decrease in plasma intact FGF23 by 24 hours postprocedure in all three subjects (0, 2, and 9 pg/mL, respectively) with normalization of blood phosphate by postprocedure day 3. Three-day renal tubular reabsorption of phosphate increased to 76%, 94%, and 95.2%, respectively; 1, 25(OH)2 vitamin D increased to 84, 138, and 196 pg/ml, respectively. All three had dramatic clinical improvement in pain and weakness. Two subjects tolerated the procedure well with no complications; one had significant prolonged procedure-related localized pain. Although surgery remains the treatment of choice, cryoablation may be an effective, less invasive, and safe treatment for patients with difficult to remove tumors or who are poor surgical candidates.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CRYOABLATION; FGF23; TIO; TUMOR-INDUCED OSTEOMALACIA

Mesh:

Substances:

Year:  2017        PMID: 28718983      PMCID: PMC5685881          DOI: 10.1002/jbmr.3219

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  13 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

3.  Radiofrequency ablation of a tumor causing oncogenic osteomalacia.

Authors:  Eric Hesse; Herbert Rosenthal; Leonard Bastian
Journal:  N Engl J Med       Date:  2007-07-26       Impact factor: 91.245

4.  Successful CT guided cryoablation of phosphaturic mesenchymal tumor in the soft tissues causing tumor-induced osteomalacia: a case report.

Authors:  Sophie Cowan; Santiago A Lozano-Calderon; Raul N Uppot; Dipti Sajed; Ambrose J Huang
Journal:  Skeletal Radiol       Date:  2016-12-05       Impact factor: 2.199

Review 5.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

6.  Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.

Authors:  Jen-Chieh Lee; Sheng-Yao Su; Chun A Changou; Rong-Sen Yang; Keh-Sung Tsai; Michael T Collins; Eric S Orwoll; Chung-Yen Lin; Shu-Hwa Chen; Shyang-Rong Shih; Cheng-Han Lee; Yoshinao Oda; Steven D Billings; Chien-Feng Li; G Petur Nielsen; Eiichi Konishi; Fredrik Petersson; Thomas O Carpenter; Kesavan Sittampalam; Hsuan-Ying Huang; Andrew L Folpe
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

7.  Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients.

Authors:  Swati Jadhav; Rajeev Kasaliwal; Nitin S Shetty; Suyash Kulkarni; Krantikumar Rathod; Bhavesh Popat; Harshal Kakade; Amol Bukan; Shruti Khare; Sweta Budyal; Varsha S Jagtap; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  J Clin Endocrinol Metab       Date:  2014-06-24       Impact factor: 5.958

Review 8.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

9.  Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation.

Authors:  Sean Tutton; Erik Olson; David King; Joseph L Shaker
Journal:  J Clin Endocrinol Metab       Date:  2012-07-26       Impact factor: 5.958

10.  Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment.

Authors:  D I Rosenthal; F J Hornicek; M W Wolfe; L C Jennings; M C Gebhardt; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1998-06       Impact factor: 5.284

View more
  6 in total

Review 1.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 2.  Phosphaturic mesenchymal tumors: what an endocrinologist should know.

Authors:  J M Boland; P J Tebben; A L Folpe
Journal:  J Endocrinol Invest       Date:  2018-02-14       Impact factor: 4.256

3.  Usefulness of 68Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia.

Authors:  Dong Yun Lee; Seung Hun Lee; Beom-Jun Kim; Wanlim Kim; Pil Whan Yoon; Sang Ju Lee; Seung Jun Oh; Jung-Min Koh; Jin-Sook Ryu
Journal:  Sci Rep       Date:  2021-01-19       Impact factor: 4.379

4.  Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.

Authors:  Iris R Hartley; Kelly L Roszko; Xiaobai Li; Karen Pozo; Jamie Streit; Jaydira Del Rivero; M Teresa Magone; Michaele R Smith; Roo Vold; Carl L Dambkowski; Michael T Collins; Rachel I Gafni
Journal:  JBMR Plus       Date:  2022-07-22

5.  Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.

Authors:  Kathryn Dahir; María Belén Zanchetta; Irinel Stanciu; Cemre Robinson; Janet Y Lee; Ruban Dhaliwal; Julia Charles; Roberto Civitelli; Mary Scott Roberts; Stan Krolczyk; Thomas Weber
Journal:  J Endocr Soc       Date:  2021-06-02

6.  Tumor-induced osteomalacia.

Authors:  Pablo Florenzano; Rachel I Gafni; Michael T Collins
Journal:  Bone Rep       Date:  2017-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.